Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Global drug industry profits set to slow, says Moody's

The credit rating agency has changed its outlook on the sector to stable from positive
Global drug industry profits set to slow, says Moody's
Moody's blamed lower pricing flexibility, the stronger US dollar and slower adoption of some new products

Profit increases in the global drug industry are likely to slow due to tougher pricing and the stronger US dollar, according to Moody's.

The credit rating agency has changed its outlook on the sector to stable from positive as a result of an expected "modest reduction" in earnings growth.

Moody's blamed lower pricing flexibility, the stronger US dollar and slower adoption of some new products for its revised expectations.

Moody's senior vice-president Michael Levesque said: "We now expect growth of 3%-4% versus our previous expectation of 4%-5%."

The agency said the changes to its forecasts were partly due to the controversy over high drug prices in the US, forcing manufacturers into reductions.

Pressure on prices in Europe and Japan was also a factor as drug patents expired and manufacturers faced competition from copy-cat producers.

Moody's said the stronger US dollar was likely to hit large US-based companies with overseas operations, but help non-US drug manufacturers.

It also noted that adoption rates for some products from large pharmaceutical companies had been slower than the agency expected.

But growth was still strong for cancer drugs, especially those in immuno-oncology like Bristol-Myers Squibb's (A2 stable) Opdivo and Merck's (A1 stable) Keytruda.

Levesque added: "Pharmaceutical companies will remain active in the M&A market as they try to cut costs, achieve greater scale and diversification and acquire pipeline drugs with high potential."

Phil-Waller.jpg


Register here to be notified of future BMY Company articles
View full BMY profile

Bristol Myers Squibb Timeline

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
Cells
April 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use